串扰
细胞生物学
生物
调解人
PRC2
抑制器
对抗
转录调控
细胞周期
融合蛋白
细胞周期进展
效应器
表观遗传学
神经科学
细胞
转录组
甲基化
下调和上调
转录因子
基因表达调控
蛋白质-蛋白质相互作用
计算生物学
化学
DNA甲基化
HEK 293细胞
细胞周期蛋白
血浆蛋白结合
自动调节
心理压抑
作者
Daniel Neville,Daniel T. Ferguson,Emily Heikamp,Zhihao Lai,Graham W. Magor,Charlene Lam,Olivia G. Dobbs,Vita Levina,Kathy Knezevic,James J. The,Shania Alex,Stephen C Suits,Bradon Rumler,Michael Uckelmann,Laure Talarmain,Enid Y. N. Lam,Andrew C. Perkins,Scott A. Armstrong,Charles C. Bell,Chen Davidovich
标识
DOI:10.1038/s41556-025-01859-8
摘要
DOT1L and Menin are essential cofactors for the oncogenic activity of MLL fusion proteins (MLL-FPs) in leukaemia. However, the mechanisms underpinning the therapeutic effects of their inhibitors remain unclear. Here we identify a critical role for the non-canonical Polycomb repressive complex 1.1 (PRC1.1) in mediating the cellular responses to DOT1L and Menin inhibitors. Menin inhibition induces PRC1.1-dependent deposition of H2AK119ub to silence a subset of MLL-FP targets, whereas DOT1L inhibition results in a genome-wide increase in H2AK119ub. We show that enhanced PRC1.1 activity arises specifically from the progressive loss of DOT1L-mediated H3K79 methylation, independent of MLL-FP displacement or transcriptional repression. This regulatory crosstalk is conserved across cell types and is driven by direct biochemical antagonism between H3K79 methylation and PRC1 activity. Together, our findings establish DOT1L as a component of transcriptional memory co-opted in leukaemia and suggest it serves as the missing link balancing the opposing forces of the MLL-Polycomb axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI